Adjuvant nivolumab may be promising for treatment of completely resected Merkel cell carcinoma
Bookmark1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in...
Read More
Oncology
Atezolizumab is a potentially effective treatment option for patients with alveolar soft part sarcoma
Bookmark1. 37% of study patients had an objective response to treatment with atezolizumab. 2....
Read More
Patritumab Deruxtecan in EGFR-mutated NSCLC post EGFR TKI and Chemotherapy
Bookmark1. The objective response rate was 29.8% (1% complete response, 66% partial response) with...
Read More
Nivolumab/Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma
Bookmark1. Pooled overall survival and progression-free survival HR were found to be 0.95 and 0.88...
Read More
Vitamin D3 supplementation may improve relapse-free survival for certain digestive tract cancers
Bookmark1. This post-hoc analysis of the AMATERASU randomized clinical trial found that, for...
Read More